Kelsey N Ryan1, Kevin B Stephenson1, Indi Trehan2, Robert J Shulman3, Chrissie Thakwalakwa4, Ellen Murray1, Kenneth Maleta4, Mark J Manary5. 1. Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri; Department of Paediatrics and Child Health, University of Malawi College of Medicine, Blantyre, Malawi. 3. Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas. 4. Department of Community Health, University of Malawi College of Medicine, Blantyre, Malawi. 5. Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri; Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas; Department of Community Health, University of Malawi College of Medicine, Blantyre, Malawi. Electronic address: manary@kids.wustl.edu.
Abstract
BACKGROUND & AIMS: Environmental enteropathy (EE) is a subclinical condition among children in the developing world, characterized by T-cell infiltration of the small-bowel mucosa and diffuse villous atrophy. EE leads to macronutrient and micronutrient malabsorption and stunting, with a resultant increased risk for infection and reduced cognitive development. We tested the hypothesis that zinc and albendazole treatments would reduce the severity of EE in rural African children. METHODS: In a randomized, double-blind, placebo-controlled trial in rural southern Malawi, asymptomatic children, 1 to 3 years old and at high risk for EE, received either a single dose of albendazole, a 14-day course of 20 mg zinc sulfate, or a placebo. Subjects were given the dual-sugar absorption test, and the ratio of lactulose to mannitol (L:M) in urine was used to determine the severity of EE at baseline and 34 days after completion of the assigned regimen. The primary outcome was the change in the L:M. RESULTS: A complete set of urine samples was obtained from 222 of 234 children enrolled and analyzed. The mean baseline L:M was 0.32 ± 0.18 among all children and did not differ among groups (normal L:M range, <0.12). At the end of the study, the L:M ratio had increased more in the placebo group (0.12 ± 0.31) than in the zinc group (0.03 ± 0.20; P < .03) or the albendazole group (0.04 ± 0.22; P < .04). CONCLUSIONS: Treatment with zinc or albendazole protects against a significant increase in the L:M ratio, a biomarker for EE, in asymptomatic rural Malawian children. These findings could provide insight into the etiology and pathogenesis of EE. Clinicaltrials.gov Number: NCT01440608.
RCT Entities:
BACKGROUND & AIMS: Environmental enteropathy (EE) is a subclinical condition among children in the developing world, characterized by T-cell infiltration of the small-bowel mucosa and diffuse villous atrophy. EE leads to macronutrient and micronutrient malabsorption and stunting, with a resultant increased risk for infection and reduced cognitive development. We tested the hypothesis that zinc and albendazole treatments would reduce the severity of EE in rural African children. METHODS: In a randomized, double-blind, placebo-controlled trial in rural southern Malawi, asymptomatic children, 1 to 3 years old and at high risk for EE, received either a single dose of albendazole, a 14-day course of 20 mg zinc sulfate, or a placebo. Subjects were given the dual-sugar absorption test, and the ratio of lactulose to mannitol (L:M) in urine was used to determine the severity of EE at baseline and 34 days after completion of the assigned regimen. The primary outcome was the change in the L:M. RESULTS: A complete set of urine samples was obtained from 222 of 234 children enrolled and analyzed. The mean baseline L:M was 0.32 ± 0.18 among all children and did not differ among groups (normal L:M range, <0.12). At the end of the study, the L:M ratio had increased more in the placebo group (0.12 ± 0.31) than in the zinc group (0.03 ± 0.20; P < .03) or the albendazole group (0.04 ± 0.22; P < .04). CONCLUSIONS: Treatment with zinc or albendazole protects against a significant increase in the L:M ratio, a biomarker for EE, in asymptomatic rural Malawian children. These findings could provide insight into the etiology and pathogenesis of EE. Clinicaltrials.gov Number: NCT01440608.
Authors: Heather C Stobaugh; Lucy B Bollinger; Sara E Adams; Audrey H Crocker; Jennifer B Grise; Julie A Kennedy; Chrissie Thakwalakwa; Kenneth M Maleta; Dennis J Dietzen; Mark J Manary; Indi Trehan Journal: Am J Clin Nutr Date: 2017-06-14 Impact factor: 7.045
Authors: Christine Marie George; Lauren Oldja; Shwapon Biswas; Jamie Perin; Gwenyth O Lee; Margaret Kosek; R Bradley Sack; Shahnawaz Ahmed; Rashidul Haque; Tahmina Parvin; Ishrat J Azmi; Sazzadul Islam Bhuyian; Kaisar A Talukder; Shahnaij Mohammad; Abu G Faruque Journal: Am J Trop Med Hyg Date: 2015-04-27 Impact factor: 2.345
Authors: Kelsey D J Jones; Barbara Hünten-Kirsch; Ahmed M R Laving; Caroline W Munyi; Moses Ngari; Jenifer Mikusa; Musa M Mulongo; Dennis Odera; H Samira Nassir; Molline Timbwa; Moses Owino; Greg Fegan; Simon H Murch; Peter B Sullivan; John O Warner; James A Berkley Journal: BMC Med Date: 2014-08-14 Impact factor: 8.775
Authors: Sarah E Burr; John Hart; Tansy Edwards; Emma M Harding-Esch; Martin J Holland; David C W Mabey; Ansumana Sillah; Robin L Bailey Journal: BMC Public Health Date: 2014-11-18 Impact factor: 3.295
Authors: Jinsheng Yu; M Isabel Ordiz; Jennifer Stauber; Nurmohammad Shaikh; Indi Trehan; Erica Barnell; Richard D Head; Ken Maleta; Phillip I Tarr; Mark J Manary Journal: Cell Mol Gastroenterol Hepatol Date: 2015-12-11